Company Analysis
Sign in

Vanda Pharmaceuticals Inc. (VNDA)

Nasdaq: VNDA · Pharmaceutical Preparations · Washington, DC · filing with the SEC since 2005
Full chart Alerts Compare
Grade6.0
◀ Past 7.4● Present 6.0▶ Future 4.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

109 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Vanda Pharmaceuticals Inc.’s names, not what it holds today.

Patents granted
109
108 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
14
Against 5 in 2024 and 14 in 2023
Applications published
195
14 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'10'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals43
Organic fine chemistry5
Medical technology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Vanda Pharmaceuticals Inc. its own name
named as the applicant on its applications, in US
0 granted
176 published
Vanda Pharmaceuticals Inc. its own name
US, as the owner printed on each patent
109 granted
19 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,502,379Ponesimod for avoiding worsening of fatigue-related symptoms in multiple sclerosis patientsPharmaceuticalsVanda Pharmaceuticals Inc.
Nov 25, 202512,478,619Method of treatment with milsaperidonePharmaceuticalsVanda Pharmaceuticals Inc.
Oct 21, 202512,447,141Liquid tasimelteon formulations and methods of use thereofPharmaceuticalsVanda Pharmaceuticals Inc.
Oct 14, 202512,440,470Liquid tasimelteon formulations and methods of use thereofPharmaceuticalsVanda Pharmaceuticals Inc.
Sep 30, 202512,427,132Method of improving sleepPharmaceuticalsVanda Pharmaceuticals Inc.
Sep 23, 202512,419,869Methods of treating multiple sclerosisPharmaceuticalsVanda Pharmaceuticals Inc.
Sep 9, 202512,409,167Pharmaceutical combination comprising a selective S1P1 receptor agonistPharmaceuticalsVanda Pharmaceuticals Inc.
Sep 2, 202512,403,134Method for improving or enhancing cognitionPharmaceuticalsVanda Pharmaceuticals Inc.
Jul 15, 202512,357,616Methods of treating multiple sclerosisPharmaceuticalsVanda Pharmaceuticals Inc.
Jun 24, 202512,336,980Dosing regimen for a selective S1P1 receptor agonistPharmaceuticalsVanda Pharmaceuticals Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387376Methods Of Treating Multiple SclerosisPharmaceuticalsVanda Pharmaceuticals Inc.
Dec 11, 20252025/0375426PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONISTPharmaceuticalsVanda Pharmaceuticals Inc.
Dec 11, 20252025/0375409Treatment of REM Behavior DisorderPharmaceuticalsVanda Pharmaceuticals Inc.
Nov 6, 20252025/0339398TREATMENT OF SLEEP DISTRUBANCES IN AUTISM SPECTRUM DISORDER PATIENTSPharmaceuticalsVanda Pharmaceuticals Inc.
Oct 30, 20252025/0332147Methods of Treating Multiple SclerosisPharmaceuticalsVanda Pharmaceuticals Inc.
Oct 16, 20252025/0320188HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEONOrganic fine chemistryVanda Pharmaceuticals Inc.
Sep 11, 20252025/0281463DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONISTPharmaceuticalsVanda Pharmaceuticals Inc.
Aug 14, 20252025/0255855METHOD OF TREATMENT WITH TRADIPITANTPharmaceuticalsVanda Pharmaceuticals Inc.
Aug 7, 20252025/0248985TREATMENT OF PARKINSON'S DISEASE AND PARKINSON'S DISEASE PSYCHOSISPharmaceuticalsVanda Pharmaceuticals Inc.
Jun 26, 20252025/0205213METHOD OF TREATMENT WITH TRADIPITANTPharmaceuticalsVanda Pharmaceuticals Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 35 · Biotechnology 2 · Organic fine chemistry 2 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VNDA · research, not advice